{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-058379","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.116991+00:00","generated_at":"2026-05-19T12:22:29.548848+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Novavax Phase 3 CIC & flu vaccine candidates show robust immune responses, well tolerated","bullets":["COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine candidates induced 2.4-5.7-fold immune responses over baseline.","Both candidates well tolerated; >98% of solicited adverse events mild or moderate in severity.","Results from initial cohort of Phase 3 trial in adults 65+; similar to licensed comparators Nuvaxovid and Fluzone HD.","Novavax continues to pursue partnering opportunities to advance further development of these programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-058379","json":"https://secwatch.observer/filing/0001104659-25-058379.json","markdown":"https://secwatch.observer/filing/0001104659-25-058379.md","text":"https://secwatch.observer/filing/0001104659-25-058379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925058379/0001104659-25-058379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925058379/tm2517661d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T12:22:29.548848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}